Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Overview of attention for article published in Journal of Clinical Oncology, February 2014

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

policy: 3 policy sources
twitter: 24 X users
patent: 1 patent

googleplus: 1 Google+ user
reddit: 1 Redditor
guideline: 4 clinical guideline sources

Readers on

mendeley: 313 Mendeley

So far, Altmetric has seen 56 X posts from 24 X users, with an upper bound of 167,892 followers.

RT @mtmdphd: Diffuse Large B-cell Lymphoma Prognosis (IPI24) - @QxMD https://t.co/k4nk4UCDEf REF: @MaurerStats et al. #JCO https://t.co/dQ2…

Diffuse Large B-cell Lymphoma Prognosis (IPI24) - @QxMD https://t.co/k4nk4UCDEf REF: @MaurerStats et al. #JCO https://t.co/dQ2X0w91f2 #lymsm

DLBCL EFS24: Reassuring News for Pts #JCO https://t.co/MvCzzrqOct #ASCOConnection https://t.co/QSWprQvAyc LI https://t.co/8coHaaaqtz #lymsm

@DrPaulyDeSantis @chadinabhan @MaurerStats has done some great work validating EFS at 24 months as an important surrogate outcome in DLBCL #lymsm https://t.co/7Lzcwbumdm

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 52 additional X posts.